Natera Inc
NTRA
Market Cap$20.6B
Close$
Earnings Call Q4 2024
February 28, 2025 - AI Summary
Strong Q4 Performance: Natera reported Q4 2024 revenues of $476 million, up 53% year-on-year, and $4 million above prior guidance. Volumes increased by 26% year-on-year, with gross margins rising significantly to 63%, up from 51% in Q4 2023.
Signatera Revenue Growth Potential: The company indicated the potential to double Signatera's revenue over the next few years as reimbursement coverage improves. Current average selling prices (ASPs) may increase towards $2,000, reflecting expected new coverage policies for existing tests that are currently unbilled.
2025 Financial Guidance: Natera has provided revenue guidance for 2025, estimating between $1.87 billion and $1.95 billion. This growth forecast is supported by expected steady volume growth, stable ASPs, and continued market share gains across business segments, including women's health and oncology.
Exclusive for Stockcircle Pro members
Sign up
$-160.91
205.7% downside
Current Fair Value
205.7% downsideOvervalued by 205.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $20.60 Billion |
|---|---|
| Enterprise Value | $19.86 Billion |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-1.53 |
| Beta | 1.79 |
| Outstanding Shares | 131,414,173 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -104.86 |
|---|---|
| PEG | 147.64 |
| Price to Sales | 13.84 |
| Price to Book Ratio | 16.92 |
| Enterprise Value to Revenue | 12.96 |
| Enterprise Value to EBIT | -82.04 |
| Enterprise Value to Net Income | -93 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.18 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Natera Inc
Naterais a pioneer and global leader in cell-free DNA testing from a simple blood draw. The mission of the company is to change the management of disease worldwide with a focus on women's health, oncology, and organ health. Natera operat...